Researchers have used a robotic method to screen tens of thousands of compounds and identified a novel small molecule derived from benzylpiperazine adamantyl diamide that inhibits EboV entry into cells by more than 99 percent. They used the inhibitor as a probe to investigate the EboV infection pathway and found that the target of the inhibitor is the cell protein Niemann-Pick C1.